Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $207,480.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $72.80, for a total value of $207,480.00. Following the transaction, the chief financial officer directly owned 171,843 shares in the company, valued at approximately $12,510,170.40. This represents a 1.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded down $1.33 during trading on Tuesday, reaching $71.92. The company had a trading volume of 580,537 shares, compared to its average volume of 381,070. The firm’s 50 day simple moving average is $79.53 and its two-hundred day simple moving average is $78.59. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a market capitalization of $1.65 billion, a PE ratio of 15.50 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the prior year, the business earned $1.80 earnings per share. The company’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new stake in ANI Pharmaceuticals in the 1st quarter worth $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at about $28,000. Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ANIP shares. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim lowered their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.